Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer.[3][4] It is a small molecule inhibitor of HER2.[6][7] It was developed by Array BioPharma and licensed to Cascadian Therapeutics (formerly Oncothyreon, subsequently part of Seattle Genetics).[8]
Common side effects include diarrhea, palmar-plantar erythrodysesthesia (burning or tingling discomfort in the hands and feet), nausea, fatigue, hepatotoxicity (liver damage), vomiting, stomatitis (inflammation of the mouth and lips), decreased appetite, abdominal pain, headache, anemia and rash.[9][10] Tucatinib may cause harm to a developing fetus or baby.[9]
Tucatinib was approved for medical use in the United States in April 2020,[9][10][11] in Australia in August 2020,[1] and in the European Union in February 2021.[4]
^ ab"Tukysa". Therapeutic Goods Administration (TGA). 21 August 2020. Archived from the original on 1 October 2020. Retrieved 22 September 2020.
^"Summary Basis of Decision (SBD) for Tukysa". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
^ abCite error: The named reference Tukysa FDA label was invoked but never defined (see the help page).
^"Tukysa Product information". Union Register of medicinal products. Retrieved 3 March 2023.
^"ONT-380 Active Against CNS Mets in HER2-Positive Breast Cancer". Cancer Network. 15 December 2015. Retrieved 17 April 2020.[permanent dead link]
^Martin M, López-Tarruella S (October 2018). "Emerging Therapeutic Options for HER2-Positive Breast Cancer". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 35 (36): e64–70. doi:10.1200/EDBK_159167. PMID 27249772.
^"Tucatinib" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council. Archived (PDF) from the original on 27 August 2021. Retrieved 31 January 2017.
^ abcCite error: The named reference FDA Tukysa PR was invoked but never defined (see the help page).
^ abCite error: The named reference FDA approval was invoked but never defined (see the help page).
^Cite error: The named reference FDA Drug Approval Package was invoked but never defined (see the help page).
Tucatinib, sold under the brand name Tukysa, is an anticancer medication used for the treatment of HER2-positive breast cancer. It is a small molecule...
also prolong survival, as can HER2 inhibitors lapatinib, neratinib, or tucatinib. Certain therapies are targeted at those whose tumors have particular...
apalutamide fexinidazole ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) tucatinib Fluticasone Furoate has moderate interactions with at least 45 other drugs...
therapeutics are also tyrosine kinase inhibitors (Lapatinib, Neratinib, and Tucatinib) and antibody-drug conjugates (ado-trastuzumab emtansine and trastuzumab...
Global Information